| |
Population
|
OTC only
|
Rx only
|
OTC + Rx
|
Total
|
|---|
|
Survey
|
T5
|
T6
|
T5
|
T6
| |
T5
|
T6
| |
T5
|
T6
| |
T5
|
T6
| |
|---|
|
Age (years)
|
n (%)
|
n (%)
|
%
|
%
|
OR (95 % CI)a
|
%
|
%
|
OR (95 % CI)a
|
%
|
%
|
OR (95 % CI)a
|
%
|
%
|
OR (95 % CI)a
|
|---|
|
Women
| | | | | | | | | | | | | | |
|
30–39
|
408 (10.4)
|
295 (4.5)
|
46.3
|
55.6
|
1.45 (1.05–1.99)
|
2.2
|
1.4
|
0.75 (0.23–2.48)
|
10.3
|
9.2
|
1.09 (0.63–1.86)
|
58.8
|
66.1
|
1.37 (1.00–1.86)
|
|
40–49
|
710 (18.1)
|
1880 (28.6)
|
44.9
|
49.3
|
1.29 (1.07–1.56)
|
5.2
|
3.8
|
0.87 (0.57–1.31)
|
10.9
|
13.6
|
1.41 (1.08–1.84)
|
61.0
|
66.6
|
1.29 (1.08–1.53)
|
|
50–59
|
637 (16.2)
|
1245 (18.9)
|
32.2
|
43.6
|
1.68 (1.36–2.07)
|
6.0
|
5.1
|
1.05 (0.68–1.61)
|
12.7
|
11.7
|
1.85 (0.71–4.80)
|
50.9
|
60.4
|
1.49 (1.23–1.79)
|
|
60–69
|
1187 (30.2)
|
1987 (30.2)
|
29.0
|
31.4
|
1.11 (0.96–1.29)
|
7.6
|
7.1
|
0.96 (0.74–1.24)
|
11.2
|
11.5
|
1.01 (0.83–1.22)
|
47.8
|
50.0
|
1.06 (0.94–1.21)
|
|
70–79
|
871 (22.2)
|
886 (13.5)
|
23.7
|
26.1
|
1.16 (0.94–1.43)
|
9.5
|
8.5
|
0.95 (0.69–1.31)
|
11.5
|
14.3
|
1.25 (1.00–1.56)
|
44.7
|
48.9
|
1.14 (0.96–1.36)
|
|
80+
|
118 (3.0)
|
288 (4.4)
|
25.4
|
25.7
|
1.15 (0.68–1.92)
|
5.9
|
8.3
|
1.18 (0.80–1.77)
|
15.3
|
13.9
|
0.98 (0.53–1.82)
|
46.6
|
47.9
|
1.15 (0.76–1.74)
|
|
30–89
|
3931 (100)
|
6581 (100)
|
32.9
|
38.9
|
1.26 (1.17–1.36)
|
6.7
|
5.7
|
0.98 (0.84–1.14)
|
11.5
|
12.5
|
1.19 (1.08–1.30)
|
51.1
|
57.2
|
1.21 (1.13–1.30)
|
|
Age–adjustedb
| | |
36.7
|
42.9
|
1.30 (1.20–1.41)
|
5.5
|
4.8
|
0.98 (0.84–1.14)
|
11.5
|
11.9
|
1.20 (1.09–1.32)
|
53.7
|
59.6
|
1.24 (1.15–1.32)
|
|
p, age trend
| | |
<.001
|
<.001
| |
<.001
|
<.001
| |
.370
|
.471
| |
<.001
|
<.001
| |
|
Men
| | | | | | | | | | | | | | |
|
30–39
|
273 (8.7)
|
211 (3.6)
|
30.4
|
39.3
|
1.58 (1.08–2.30)
|
1.8
|
1.9
|
1.23 (0.32–4.64)
|
4.4
|
5.2
|
1.40 (0.60–3.29)
|
36.6
|
46.5
|
1.55 (1.08–2.22)
|
|
40–49
|
569 (18.1)
|
1646 (27.9)
|
27.2
|
33.6
|
1.45 (1.18–1.78)
|
2.6
|
3.8
|
1.69 (0.97–2.95)
|
3.3
|
6.7
|
2.39 (1.45–3.94)
|
33.2
|
44.1
|
1.56 (1.29–1.89)
|
|
50–59
|
332 (10.6)
|
1123 (19.0)
|
18.4
|
24.0
|
1.34 (1.01–1.79)
|
6.3
|
4.0
|
0.68 (0.42–1.13)
|
2.4
|
5.8
|
2.63 (1.25–5.51)
|
27.1
|
33.8
|
1.29 (1.01–1.65)
|
|
60–69
|
1108 (35.2)
|
1939 (32.9)
|
14.0
|
18.4
|
1.37 (1.13–1.66)
|
5.7
|
4.5
|
0.84 (0.61–1.15)
|
4.5
|
5.2
|
1.19 (0.87–1.63)
|
24.2
|
28.1
|
1.21 (1.04–1.41)
|
|
70–79
|
769 (24.5)
|
803 (13.6)
|
10.4
|
14.5
|
1.52 (1.13–2.06)
|
5.6
|
6.7
|
1.31 (0.88–1.94)
|
4.3
|
5.6
|
1.43 (0.91–2.24)
|
20.3
|
26.8
|
1.46 (1.17–1.83)
|
|
80+
|
94 (3.0)
|
178 (3.0)
|
10.6
|
10.1
|
0.93 (0.42–2.05)
|
7.5
|
5.6
|
0.75 (0.28–2.05)
|
1.1
|
4.5
|
4.27 (0.53–34.60)
|
19.2
|
20.2
|
1.05 (0.56–1.96)
|
|
30–89
|
3145 (100)
|
5900 (100)
|
17.3
|
23.7
|
1.46 (1.32–1.61)
|
4.9
|
4.5
|
1.02 (0.84–1.23)
|
3.9
|
5.8
|
1.59 (1.31–1.92)
|
26.1
|
33.9
|
1.38 (1.27–1.50)
|
|
Age–adjustedb
| | |
21.3
|
27.1
|
1.48 (1.33–1.65)
|
4.3
|
3.9
|
1.03 (0.85–1.24)
|
3.5
|
5.7
|
1.57 (1.29–1.91)
|
29.1
|
36.7
|
1.39 (1.27–1.52)
|
|
p, age trend
| | |
<.001
|
<.001
| |
.001
|
.001
| |
.727
|
.127
| |
<.001
|
<.001
| |
|
p, sex
| | |
<.001
|
<.001
| |
.037
|
.046
| |
<.001
|
<.001
| |
<.001
|
<.001
| |
- The proportion of analgesic users last four weeks and odds ratios for use of analgesics in Tromsø 6 compared to Tromsø 5, according to age, sex and prescription category. The Tromsø Study: Tromsø 5 (2001–02, n = 7076) and Tromsø 6 (2007–08, n = 12,481)
-
OTC “over-the-counter”, non-prescription, Rx prescription, T5 Tromsø 5, T6 Tromsø 6, CI confidence interval, OR odds ratio
-
aReference category: non-users of both OTC and Rx
-
bPrevalence estimates age-adjusted with the Norwegian population 01.01.2008 as standard population
